Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
BioCryst Pharmaceuticals, Inc. logo

NASDAQ · BCRX

BioCryst Pharmaceuticals, Inc.

Healthcare · Biotechnology

$7.95

Down-$0.15 (-1.85%)

Updated Oct 7, 2026, 2:50 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.6B
P/E ratio
-181.47
Dividend yield
0.00%
52-week range
$7.79 – $11.22
Volume
3.94M
Avg. volume
4.95M

Price performance · BCRX

BCRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

BCRX closed at $7.95 after 21 trading sessions, down 12.30% for the selected period.

Last close
$7.95
Period change
-12.30%
Period low
$7.95
Period high
$9.07
Daily close
View OHLC price history
BCRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$8.15$8.15$7.87$7.953.94M
Oct 5, 2026$8.17$8.25$7.915$8.104.71M
Oct 2, 2026$8.12$8.20$7.92$8.176.15M
Oct 1, 2026$8.30$8.38$8.065$8.126.87M
Sep 30, 2026$8.28$8.42$8.1841$8.3313.1M
Sep 29, 2026$8.42$8.50$8.22$8.275.01M
Sep 28, 2026$8.555$8.66$8.335$8.474.35M
Sep 25, 2026$8.52$8.63$8.40$8.593.67M
Sep 24, 2026$8.535$8.65$8.395$8.524.85M
Sep 23, 2026$8.75$8.86$8.455$8.574.47M
Sep 22, 2026$8.87$9.035$8.72$8.783.44M
Sep 21, 2026$8.75$8.845$8.575$8.763.46M
Sep 18, 2026$8.60$8.835$8.4925$8.6812.75M
Sep 17, 2026$8.54$8.73$8.425$8.705.22M
Sep 16, 2026$8.15$8.45$8.11$8.435.86M
Sep 15, 2026$8.19$8.23$8.0201$8.166.11M
Sep 14, 2026$8.17$8.38$8.095$8.235.1M
Sep 11, 2026$8.30$8.3972$8.105$8.123.59M
Sep 10, 2026$8.34$8.46$8.045$8.299M
Sep 9, 2026$9.07$9.23$8.80$8.8055.15M
Sep 8, 2026$9.122$9.40$8.96$9.0659.69M

Latest BCRX news

The latest Smart Investors Daily articles mentioning BCRX.

Stock researchCompany · Overview

BCRX research

Overview

Company profile and research snapshot.

Company profile

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.40
Implied upside
—
Analysts
—
BCRX recent ratings
DateFirmRatingTarget
Sep 30, 2026JP MorganNeutral—
Sep 10, 2026RBC CapitalSector Perform—
Sep 8, 2026NeedhamBuy—
Aug 6, 2026RBC CapitalOutperform—
Aug 6, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 5, 2026

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development. The SAB will provide independent scientific and strategic guidance as the Company advances

Yahoo · Sep 29, 2026

Claude AI Just Bought These 2 Pharma Stocks

Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic’s Claude AI recently sold its positions in Ardelyx Inc. (NASDAQ: ARDX) and Aris Mining Corp. (NYSE: ARIS) and replaced them with Syndax Pharmaceuticals Inc. […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By